Is Denison Mines (DNN) One of the Best Nuclear Power Stocks to Buy According to Wall Street Analysts?
Denison Mines (DNN) was listed among 15 nuclear power stocks “to buy” by Wall Street analysts. On May 14, Scotiabank analyst Orest Wowkodaw raised its price target to C$7.50 from C$6 and kept an Outperform rating, implying 62% upside. The company reported Q1 loss per share of C$0.13 and revenue down ~20% YoY to C$1.11M. Denison said it received approval to start Phoenix construction in Feb 2026, targeting uranium production in mid-2028.
Analyst target hike plus a concrete regulatory milestone (Phoenix approval) improves the project timeline narrative, supporting bullish positioning despite weak Q1 revenue and EPS loss.
Scotiabank raised DNN’s price target to C$7.50 (from C$6) and cited regulatory approval to start Phoenix construction, targeting mid-2028 production.
Near-term upside bias as traders price in higher probability of mid-2028 uranium production and future free cash flow; follow-through depends on subsequent project execution and funding.
Background
Denison Mines is a uranium developer focused on the Athabasca Basin; the article ties an analyst target increase to a Phoenix project regulatory approval and expected production start.
Why it matters
The combination of (1) a raised analyst price target and (2) regulatory approval to commence construction can shift trader expectations for project timing and future cash generation, even with near-term losses.
Market relevance
Material for DNN because it pairs a fresh analyst target change with a specific regulatory milestone that affects the project’s probability-weighted timeline.
Market effects
Reinforces the uranium development ‘option value’ trade: regulatory approvals and construction starts can re-rate developers even when near-term financials are weak.
Limited direct regional impact; Phoenix asset is in Canada’s Athabasca Basin, relevant mainly to Canada-focused resource sentiment.
Supports broader nuclear/uranium supply narrative, but the article is single-company focused.
Alternative perspectives
The piece highlights upside framing while Q1 showed revenue down ~20% YoY and an EPS loss; execution/capex and commodity-price risk could overwhelm the target upgrade.
No updated production cost curve, funding plan, or detailed capex schedule is provided; regulatory approval is a milestone, but not proof of on-time commissioning or margin expansion.
Key entities
- companyDenison Mines Corp.
Subject of the article; uranium developer with Phoenix asset regulatory approval and mid-2028 production expectation.
- analyst_firmScotiabank
Raised DNN’s price target to C$7.50 and maintained an Outperform rating.
